4284
Acknowledgements
We gratefully acknowledge the ®nancial support of grant DAMD 17-98-1-8544 from the US
Army Department of Defense Prostate Cancer Research Program and grant GM61242 from the
National Institutes of Health.
References
1. (a) Nishiguchi, T.; Fujisaki, S.; Ishii, Y.; Yano, Y.; Nishida, A. J. Org. Chem. 1994, 59, 1191±1195; (b) Lezno,
C. C. Acc. Chem. Res. 1978, 11, 327±333; (c) Kata, Y.; Fujiwara, Y.; Asano, Y. Bioorg. Med. Chem. Lett. 1999, 9,
3207±3210. (d) Lalonde, M.; Chan, T. H. Synthesis 1985, 817±845.
2. (a) Raederstor, D.; Shu, A. Y. L.; Thompson, J. E.; Djerassi, C. J. Org. Chem. 1987, 52, 2337±2346;
(b) Kulkarni, B. A.; Chattopadhyay, S.; Chattopadhyay, A.; Mamdapur, V. R. J. Org. Chem. 1993, 58, 5964±
5966.
3. (a) Wilkinson, C. G. In Comprehensive Organic Chemistry; Stoddart, J. F., Ed.; Pergamon Press: New York, 1979;
Vol. 1, pp. 681±687; (b) Furhop, J.; Penzlin, G. Organic Synthesis; Verlag Chemie: Weinheim, 1983; pp. 143±151;
(c) Ogawa, H.; Chihara, T.; Taya, K. J. Am. Chem. Soc. 1985, 107, 1365±1369.
4. (a) Murahashi, S.; Oda, Y.; Naota, T. Chem. Lett. 1992, 2237, and references cited therein; (b) Grin, B. E.;
Jarman, M.; Reese, C. B.; Sulston, J. E. Tetrahedron 1967, 23, 2301±2313; (c) Ortuno, R. M.; Merce, R.; Font, J.
Tetrahedron Lett. 1986, 27, 2519±2522.
5. (a) Terao, O.; Akamatsu, M.; Achiwa, K. Chem. Pharm. Bull. 1991, 39, 823±825; (b) Houille, O.; Schmittberger,
T.; Uguen, D. Tetrahedron Lett. 1996, 37, 625±628; (c) Farquhar, D.; Khan, S.; Wilkerson, M. C.; Anderson, B. S.
Tetrahedron Lett. 1995, 36, 655±658.
6. McDougal, P. G.; Rico, J. G.; Oh, Y.-I.; Condon, B. D. J. Org. Chem. 1986, 51, 3388±3390.
7. Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 3rd ed.; Wiley-Interscience: New York,
1999; Chapter 2, pp. 141±142.
8. The conditions we tried but failed to give any silylated products include: (a) TBDPSCl (1.05 equiv.), DIEA (10
equiv.), CH2Cl2, rt, 36 h; (b) TBDPSCl (1.05 equiv.), Et3N (10 equiv.), CH2Cl2, rt, 24 h; (c) TBDPSCl (1.05
equiv.), Et3N (10 equiv.)/DMAP (0.05 equiv), CH2Cl2, rt, 24 h; (d) TBDPSCl (1.05 equiv.), DMAP (10 equiv.),
CH2Cl2, rt, 24 h; (e) TBDPSCl (1.05 equiv.), pyridine, rt, 24 h; (f) TBDPSCl (1.05 equiv.), imidazole (5 equiv.),
DMF, rt, 24 h; (g) TBDPSCl (1.05 equiv.), NaH (1 equiv.), THF, 0ꢀC±rt, 3 h.
9. Ritchie, C. D.; Lu, S.-Z. J. Am. Chem. Soc. 1989, 111, 8542±8543.
10. In a typical procedure, DIEA (10 mmol, 1.7 mL) and DMF (3 mL) form two immiscible solution phases at room
temperature. Using NMR, we found that the top DIEA phase contained about 18% DMF (mol) and the bottom
DMF phase contained about 16% DIEA. TLC analysis indicated that reactants used in our experiments were
mainly in the bottom DMF phase. We also found that using saturated DIEA solution in DMF as the reaction
media decreased both the reaction yield and the selectivity of silylation.
11. Acetone±hexane was found to be a better eluting solvent system than the commonly used ethyl acetate/hexane for
the puri®cation and structure assignment of the monosilylated 1,n-primary diols, since ethyl acetate can be
strongly retained in compounds containing hydroxyl groups and it is hard to remove completely in vacuo.
12. Selected 1H NMR (200 MHz, CDCl3) data: ꢀ ppm compound 1: 7.60 (dd, 2H, J=7.5, 1.3 Hz), 7.41±7.26 (m, 3H),
4.13±3.89 (m, 6H), 3.08 (t, 2H, J=6.6 Hz), 1.98 (br s, 2H, OH), 1.18 (t, 3H, J=7.1 Hz); compound 2: 7.76±7.20
(m, 15H), 4.24±4.12 (m, 2H), 4.03±3.90 (m, 4H), 2.55 (dd, 1H, J=5.7, 4.0 Hz, OH), 1.08 (t, 3H, J=7.8 Hz), 1.06
(s, 9H); compound 3: 7.76±7.67 (m, 10H), 7.44±7.26 (m, 15H), 4.36 (Abq, 2H, Áꢁ=14.0 Hz, J=9.5 Hz), 3.65 (q,
2H, J=6.8Hz), 1.05 (s, 18H), 0.82 (t, 3H, J=7.1 Hz); mono-TBDPS-4: 7.78±7.73 (m, 4H), 7.49±7.43 (m, 6H),
3.85±3.80 (m, 2H), 3.74 (br s, 2H), 2.45 (br s, 1H, OH), 1.15 (s, 9H); mono-TBDPS-5: 7.75±7.70 (m, 4H), 7.45±7.42
(m, 6H), 3.88 (t, 2H, J=5.6 Hz), 3.87 (t, 2H, J=5.8 Hz), 2.54 (br s, 1H, OH), 1.80 (q, 2H, J=5.7 Hz), 1.10 (s, 9H);
mono-TBDPS-6: 7.82±7.68 (m, 4H), 7.52±7.38 (m, 6H), 3.60 (d, 2H, J=5.5 Hz), 3.56 (s, 2H), 2.68 (t, 1H, J=5.5
Hz, OH), 1.42±0.75 [m, 23H, including 1.12 (s, 9H), 0.92 (t, 3H, J=6.1 Hz), 0.81 (t, 3H, J=6.5 Hz)]; mono-
TBDPS-7: 7.70±7.65 (m, 4H), 7.45±7.39 (m, 6H), 3.53±3.33 (m, 4H), 1.85 (br s, 2H, NH2), 1.09 (s, 9H), 1.04 (s,
3H); mono-TBDPS-8: 7.83±7.79 (m, 4H), 7.50±7.45 (m, 4H), 7.33 (br s, 3H), 4.89 (s, 2H), 4.73 (s, 2H), 3.20 (br s,
1H, OH), 1.17 (s, 9H); mono-TBDPS-9: 7.76±7.71 (m, 4H), 7.45±7.41 (m, 6H), 3.73 (t, 2H, J=6.2 Hz), 3.64 (t, 2H,